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Abstract An oligopeptide containing three consecutive Thr
residues mimicking the tandem repeat portion of MUC2
(PTTTPLK) was investigated for the acceptor specificity to
UDP-N-acetyl-D-galactosamine :peptide N-acetylgalactosami-
nyltransferase isozymes, UDP-N-acetyl-D-galactosamine:pep-
tide N-acetylgalactosaminyltransferase-T1, T2 and T3. The
enzymatic reaction products were fractionated by the reversed-
phase high performance liquid chromatography, then character-
ized by matrix-assisted laser desorption ionization time of flight
mass spectrometry and by a peptide sequencing analysis. A
maximum of two, one or three N-acetyl-D-galactosamine
residues was transferred by UDP-N-acetyl-D-galactosamine:
peptide N-acetylgalactosaminyltransferase-T1, T2 or T3, re-
spectively. The preferential orders of N-acetyl-D-galactosamine
incorporation were Thr-2, then Thr-4 for UDP-N-acetyl-D-
galactosamine :peptide N-acetylgalactosaminyltransferase-T1,
Thr-2 for UDP-N-acetyl-D-galactosamine:peptide N-acetylga-
lactosaminyltransferase-T2 and Thr-4, Thr-3, then Thr-2 for
UDP-N-acetyl-D-galactosamine :peptide N-acetylgalactosami-
nyltransferase-T3.
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1. Introduction
UDP-N-acetyl-D-galactosamine (GalNAc):polypeptide Gal-
NAc-transferases (GalNAc-Ts, EC 2.4.1.41) transfer GalNAc
to Ser and Thr residues in a polypeptide. Four isozymes of
human GalNAc-T have been identi¢ed and characterized to
date: T1, T2 [1], T3 [2] and T4 [3]. Additional isozymes have
been identi¢ed in rat and Caenorhabditis elegans [4^6]. Gene
cloning studies suggested that there are many GalNAc-T iso-
forms having di¡erent acceptor substrate speci¢cities [7]. For
example, Wandall and co-workers reported, using recombi-
nant human GalNAc-T1, T2 and T3, that these three enzymes
had di¡erent kinetic properties where T1 and T3 showed a
strong preference for TNTS and T2 showed a preference for
TNST. However, they did not have a positional preference
towards Thr residues in the tandem repeat portion of
MUC1 mucin [8].
Previously, we reported that consecutive Thr residues from
the MUC2 tandem repeat domain were fully glycosylated us-
ing detergent-soluble microsome fractions from the human
colon carcinoma cell line LS174T as a source of GalNAc-Ts
[9]. In the present study, we focused to de¢ne substrate spe-
ci¢cities towards three consecutive Thr residues mimicking
MUC2 tandem repeats, PTTTPLK. Di¡erent speci¢cities
and di¡erent kinetic properties were observed with GalNAc-
T1, T2 and T3.
2. Materials and methods
2.1. Synthesis of acceptor substrates
Synthetic oligopeptides used as acceptor substrates were synthesized
with a Model 9020 peptide synthesizer (Milligen, Burlington, MA,
USA). Peptides corresponding to the tandem repeat domain of the
MUC2 mucin core polypeptide (PTTTPITTTTTVTPTPTPTGTQT)
[10] were synthesized with a lysine residue attached at the C-terminus.
These are PTTTPITTTTK (FM2-1), TVTPTPTPTGK (FM2-3) and
PTTTPLK (FM2-12). All peptides were labelled with £uorescein iso-
thiocyanate at its N-terminal amino acid at pH 7.5 adjusted with 100
mM HEPES bu¡er.
2.2. Preparation of recombinant GalNAc-Ts
Soluble recombinant GalNAc-T1, T2 and T3 were prepared as
described previously [8]. Brie£y, plasmid pAcGP67-GalNAc-T1-sol,
pAcGP67-GalNAc-T2-sol and pAcGP67-GalNAc-T3-sol were co-
transfected with Baculo-GOLD DNA (Pharmingen) to Sf9 cells. Re-
combinant GalNAc-T1, T2 and T3 were puri¢ed from the spent me-
dia. One unit of enzyme is de¢ned as the amount of enzyme that will
transfer 1 Wmol of GalNAc in 1 min using di¡erent acceptor sub-
strates [8].
2.3. Assays of GalNAc transferase activity
The standard enzyme reaction mixture consisted of 20 mM HEPES
bu¡er (pH 7.5), 5 mM MnCl2, 5 mM 2-mercaptoethanol, 0.1% Triton
X-100, 1 mM UDP-GalNAc (Sigma, St. Louis, MO, USA), 20 WM
peptide and 0.25 mU recombinant enzyme or 100 Wg microsome frac-
tion from the LS174T human colon carcinoma cell line [9] in a ¢nal
volume of 50 Wl. Reactions were performed at 37‡C for up to 24 h and
were terminated by adding 300 Wl of 5 mM EDTA. An equal amount
of additional enzyme and UDP-GalNAc was added after 6 h. For
kinetic studies, 0.1 mU of recombinant enzyme and UDP-
[3H]GalNAc (0.1 mCi, Dupont-NEN, Boston, MA, USA) were
used. Reaction mixtures were applied on columns packed with C18-
silica, washed with solvent A (0.05% tri£uoroacetic acid (TFA) in
water) and eluted with solvent B (0.05% TFA, 70% propanol in ace-
tonitrile). Radioactivity incorporated into peptides was measured with
a liquid scintillation counter using RedyCap (Beckman, Fullerton,
CA, USA).
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2.4. Monitoring of in vitro O-glycosylation by reversed-phase HPLC
The glycosylated peptides were separated by reversed-phase high
performance liquid chromatography (HPLC) (JASCO, Tokyo, Ja-
pan). A PURESIL (C18, 6U150 mm, Nihon Waters, Tokyo, Japan)
was used. The column was eluted with a linear gradient ranging from
10 to 30% solvent B in solvent A at a £ow rate of 2 ml/min for 30 min.
Eluates were monitored by the £uorescence intensity at 520 nm (ex:
492 nm).
2.5. Matrix-assisted laser desorption ionization mass spectrometry
analysis of glycosylated peptides (MALDI-TOF MS)
Glycosylated peptides were applied on a tip and mixed with a
10 mg/ml solution of K-cyano-4-hydroxycinnamic acid dissolved in
0.1% TFA-50% ethanol in water. All mass spectra were obtained on
a Voyager Elite (Nippon PerSeptive Biosystems, Tokyo, Japan) in the
linear mode with the delayed extraction setting.
2.6. Amino Acid Sequencing
Pulsed liquid Edman degradation amino acid sequencing of glyco-
peptides was performed on the Applied Biosystems 490 Procise pro-
tein sequencing system (Perkin Elmer, Norwalk, CT, USA). With this
system, a phenylthiohydantoin (PTH) derivative of GalNAc-attached
Thr was identi¢ed as a pair of peaks eluted near the positions of PTH-
Ser and PTH-Thr [11]. Amino acid sequencing of fully glycosylated
peptide (PTGalNAcTGalNAcTGalNAcPLK) con¢rmed these eluting posi-
tions.
3. Results
3.1. Incorporation of GalNAc into three consecutive threonine
residues using a microsomal fraction of LS174T cells
We reported previously that the FM2-1 peptide
(PTTTPITTTTLK) having three and four consecutive Thr
residues was fully glycosylated by a microsome fraction of
the colon carcinoma cell line LS174T (Iida, S. et al., submitted
for publication). An oligopeptide mimicking the N-terminal
portion of FM2-1 (FM2-12, PTTTPLK) was prepared and
examined for whether the crude enzyme also achieved com-
plete glycosylation. FM2-12 peptide was incubated with the
microsome fraction from colon carcinoma cell line LS174T up
to 18 h and subjected to reversed-phase HPLC. Four peaks
including the original oligopeptide were observed. Materials
corresponding to these peaks were isolated and analyzed by
MALDI-TOF MS. The results showed that three GalNAc
residues can be transferred in the presence of the microsome
fraction to the FM2-12 peptide (Fig. 1). The major peak from
the reversed-phase HPLC separation gave a mass of 1758.5
(Fig. 1d), indicating that three GalNAc residues were incor-
porated. Peptides with one or two GalNAc residues were also
Fig. 1. Representative pro¢les of MALDI-TOF MS of glycosylated
FM2-12 peptide separated by reversed-phase HPLC. FM2-12 pepti-
des were incubated with detergent-solubilized microsome fractions
from human colon carcinoma LS174T cells for 18 h. The products
were separated by reversed-phase HPLC on a C18 column. Eluates
corresponding to four major peaks were pooled and evaporated to
dryness. Analysis with MALDI-TOF MS was performed as previ-
ously described [9]. Mass indicates (M+H)+form. a: The pro¢le of
unglycosylated FM2-12 peptide (predicted mass: 1146.3). b: FM2-
12 peptide with a single GalNAc residue attached (predicted mass:
1349.5). c: FM2-12 peptide with two GalNAc residues attached
(predicted mass: 1552.7). d: FM2-12 peptide with three GalNAc
residues attached (predicted mass: 1755.9).
Fig. 2. Elution pro¢les of FM2-12 peptides incubated with recombi-
nant GalNAc-T1, T2 or T3 on the reversed-phase HPLC with a
C18 column. FM2-12 peptide was incubated with each recombinant
GalNAc-T for the indicated periods and separated by reversed-
phase HPLC. After incubation for 6 h, additional enzyme and
UDP-GalNAc were added as indicated by (+). (1), (2) and (3) indi-
cated eluting positions of the peptide with one, two and three Gal-
NAcs attached as revealed by MALDI-TOF MS.
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observed having masses of 1350.6 and 1554.6, respectively
(Fig. 1b, c), which were prominent when the incubation
time was less than 6 h. Thus, the FM2-12 peptide was shown
to be useful as a good acceptor of GalNAc-Ts.
3.2. Acceptor substrate speci¢city of three isozymes,
GalNAc-T1, T2 and T3
To de¢ne acceptor speci¢cities of GalNAc-T1, T2 and T3
to the three consecutive Thr residues in FM2-12, this peptide
was used as an acceptor for recombinant GalNAc-Ts. The
peptide was incubated with recombinant GalNAc-T1, T2 or
T3 for various time periods. The degree of glycosylation was
monitored with reversed-phase HPLC (Fig. 2). Each peak was
analyzed by MALDI-TOF MS, which revealed the number of
attached GalNAc residues (data not shown). Under the con-
dition used, GalNAc-T1 transferred a maximum of 2 mol of
GalNAc residues within a short period. However, even after a
prolonged incubation and with supplemented recombinant
GalNAc-T1, an additional peak corresponding to the peptide
with three GalNAc residues was not observed. With the same
amount of GalNAc-T2, one GalNAc was transferred to the
FM2-12 peptide after 24 h incubation. A small peak, appar-
ently corresponding to the same glycopeptide with two Gal-
NAc residue as seen with GalNAc-T1, was observed after
prolonged incubation with an addition of GalNAc-T2 (not
shown). Therefore, GalNAc-T1 and GalNAc-T2 are clearly
di¡erent in their acceptor speci¢city. The preferential occu-
pancy of GalNAc incorporation into three consecutive Thr
residues by GalNAc-T1 was apparently two residues whereas
that by GalNAc-T2 was one residue. On the contrary, Gal-
NAc-T3 transferred three GalNAc to FM2-12 peptide within
a 12 h time period. A peptide with two GalNAc residues
formed with GalNAc-T3 eluted at a retention time of 13.5
min, which was di¡erent from the retention time of similar
products obtained by the incubation of FM2-12 with Gal-
NAc-T1 (15.1 min). Thus, apart from the di¡erent occupancy,
GalNAc-T3 seemed to perform glycosylation in a reverse or-
der compared to T1 and T2.
3.3. Identi¢cation of N-acetylgalactosaminylated threonine
residues
Glycopeptides corresponding to three peaks were subjected
to the amino acid sequencing analysis (Fig. 3). Analysis of the
FM2-12 peptide with three attached GalNAc residues gener-
ated by the action of GalNAc-T3 (Fig. 3f) revealed that the
PTH derivative of GalNAc-Thr was identi¢ed as a pair of
peaks near the positions of PTH-Ser and PTH-Thr [10]. The
peptide with a single GalNAc residue generated by the action
of GalNAc-T1 was shown to have GalNAc at Thr-2 (Fig. 3b).
The second GalNAc residue was shown to be attached to Thr-
Fig. 3. Pro¢les of amino acid sequencing chromatograms of the oligopeptide FM2-12 and its derivatives containing incorporated GalNAc resi-
dues after incubation with GalNAc-T1, T2 and T3. Peaks after separation by the reversed-phase HPLC were analyzed on the Applied Biosys-
tems 490 Procise protein sequencing system. a: Untreated FM2-12. b and d: FM2-12 with one GalNAc residue. c and e: FM2-12 with two
GalNAc residues. f : FM2-12 with three GalNAc residues. Samples shown in b and c were obtained from an incubation mixture with recombi-
nant GalNAc-T1. d, e and f were obtained from an incubation mixture with recombinant GalNAc-T3. Asterisks indicate putative peaks of
PTH derivatives of GalNAc-Thr (TGalNAc).
Table 1
Preferential orders of the incorporation of GalNAc residues into a
synthetic peptide FM2-12 mimicking a portion of the tandem repeat
sequence of MUC2 incubated with UDP-GalNAc and GalNAc-T1,
T2 or T3
Pro Thr-2 Thr-3 Thr-4 Pro Leu Lys
T1 1 ^ 2
T2 1 ^ ^
T3 3 2 1
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4 (Fig. 3c). GalNAc-T2 seemed to be di¡erent from GalNAc-
T1 because Thr-4 was only marginally glycosylated by this
enzyme. In contrast, the peptide with a single GalNAc residue
generated by the action of GalNAc-T3 was shown to have a
glycosylated Thr-4 (Fig. 3d). The second GalNAc was appar-
ently transferred to Thr-3 (Fig. 3e). Therefore, the preferential
acceptor site for GalNAc-T3 should be di¡erent from that of
GalNAc-T1 and T2. The estimated order of the GalNAc in-
corporation is summarized in Table 1. In the reversed-phase
HPLC pro¢le of the product with GalNAc-T3, an additional
peak eluted slightly earlier than PTTTGalNAcPLK. The se-
quence of this peptide was not analyzed due to the amount
of available sample but is likely to be PTTGalNAcTPLK.
3.4. Kinetic properties of three isozymes
Two oligopeptides corresponding to two di¡erent domains
of the tandem repeat portion of MUC2 and FM2-12 peptide
were compared for their acceptors speci¢city for GalNAc-T1,
T2 and T3 (Table 2) using kinetic analysis as a parameter.
Under the condition used in this analysis, the ¢rst GalNAc
was incorporated. The FM2-1 and FM2-3 peptide contain
consecutive and alternative Thr residues, respectively. The
Vmax of GalNAc-T1 was high with FM2-1 and FM2-3 (51.5
and 50.2 pmol/min). The Vmax of T2 and T3 was higher with
FM2-3 than with FM2-1 or FM2-12. Also, the Km of Gal-
NAc-T2 with FM2-3 was much lower than that with FM2-1
or FM2-12. These results indicated that GalNAc-T1, T2 and
T3 possessed di¡erent speci¢cities towards consecutive and
alternating Thr residues. Also, the results suggested that
FM2-12 was a suitable model of an acceptor with consecutive
Thr residues.
4. Discussion
It is widely accepted that the glycosylation sites and the
pattern of elongation of O-glycan on mucins depends both
on the type of glycosyltransferases involved and on the struc-
tures of core polypeptides [12^14]. The pro¢le of O-glycan
attachment on MUC1 has been a focus of attention and it
is believed that MUC1 of mammary fat globule contained
more O-glycans than carcinoma-associated MUC1, although
little is known about the distribution of O-glycan in MUC2,
which contains consecutive Thr residues [10]. In the present
study, substrate speci¢cities of GalNAc-T1, T2 and T3 to-
wards three consecutive Thr residues in a peptide mimicking
the tandem repeat sequence of MUC2, PTTTPLK, was inves-
tigated. In this peptide, Leu was used in place of Ile in the
MUC2 sequence. GalNAc-T3 was shown to have a unique
acceptor speci¢city di¡erent from that of T1 or T2. (i) The
preferential Thr residue of the initial GalNAc attachment was
di¡erent from that of T1 or T2. (ii) All three Thr residues
were derivatized with GalNAc by the action of T3 but not
T1 or T2. These three enzymes were previously shown to
share a similar acceptor site speci¢city towards the tandem
repeat sequence of MUC1, which has three Thr residues sep-
arated within its tandem repeat unit [8]. Thus, GalNAc-T3
might play an important role in the glycosylation of consec-
utive Thr residues, at least when relatively short peptides used
in this study were the substrate. In the present study, we used
acceptor substrates with very short £anking sequences and
attached £uorescein that might in£uence their acceptor specif-
icity as indicated by Nishimori et al [12]. It was suggested by
Nehrke and co-workers that charged amino acid residues at
the amino-terminal side of Thr suppressed the GalNAc incor-
poration [15].
Three consecutive Thr residues of the tandem repeat por-
tion of MUC2 were also shown to be completely glycosylated
by a microsome fraction of LS174T colon carcinoma cells.
Furthermore, the attachment positions of GalNAc residues
of partially glycosylated FM2-1 in the presence of the micro-
some fraction was similar to those after incubation with Gal-
NAc-T3 (not shown). These results suggest that the pattern of
GalNAc incorporation into MUC2 in the presence of micro-
some fractions of LS174T cells may be attributed to GalNAc-
T3. Because GalNAc-T3 was not previously detected in nor-
mal colonic epithelia [2], the expression might be associated
with the growth of malignant epithelial cells in colons. Re-
cently, Bennett and co-workers reported that two sites in the
MUC1 tandem repeat portion, left unglycosylated after other
GalNAc-Ts glycosylated the ¢rst three sites, were glycosylated
by recombinant GalNAc-T4 [3]. Therefore, GalNAc-T4 might
also contribute to dense glycosylation of MUC2 peptides gen-
erated in the presence of the microsome fraction of LS174T
cells if this enzyme is expressed.
Using recombinant GalNAc-Ts and MUC2 peptide
(PTTTPISTTTMVTPTPTPTC), kinetic parameters of Gal-
NAc-T1, T2 and T3 were previously compared by Wandall
and co-workers [8]. In the present study, the detailed speci¢c-
ity towards two di¡erent portions of the tandem repeat se-
quence of MUC2 with consecutive or alternating Thr residues
was examined. Therefore, their and our results should not be
directly compared. None the less, GalNAc-T2 showed a low
Km value with FM2-3 which corresponds to a portion having
alternating Thr residues. This result was consistent with Wan-
dall and co-workers’ ¢nding showing that GalNAc-T2 had a
high a⁄nity with the MUC2 peptide. Although alternating
Thr residues were observed to serve as preferential substrates
of bovine GalNAc-T1 [16], the signi¢cance of such a sequence
in the regulation of O-glycosylation remains to be elucidated
In summary, the di¡erence in the acceptor speci¢city of
Table 2
Kinetics of GalNAc-T1, T2 or T3 when FM2-1, FM2-12 and FM2-3 are used as acceptors. The Km and Vmax values are calculated by the ini-
tial incorporation of [3H]GalNAc into these peptides as described in Section 2
T1 T2 T3
Km (WM) Vmax (pmol/min) Km (WM) Vmax (pmol/min) Km (WM) Vmax (pmol/min)
FM2-1
PTTTPITTTTK 23.9 51.5 25.2 4.5 30.7 8.3
FM2-12
PTTTPLK 37.4 38.5 27.9 2.4 80.2 9.5
FM2-3
TVTPTPTPTGK 16.0 50.2 8.7 28.2 50.4 61.8
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GalNAc-Ts strongly suggests that O-glycosylation of mucins
is a highly regulated process. Thus, the pattern of O-glyco-
sylation should have a biological niche yet to be explored.
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